Moteur de recherche d’entreprises européennes

Financement de l’UE (9 365 095 €) : Accélérer la traduction des jumeaux virtuels vers une prise en charge personnalisée des patients atteints de lipothérapie graisseuse Hor01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Accélérer la traduction des jumeaux virtuels vers une prise en charge personnalisée des patients atteints de lipothérapie graisseuse

The ARTEMIs project aims to consolidate existing computational mechanistic and machine-learning models at different scales to deliver ‘virtual twins’ embedded in a clinical decision support system (CDSS). The CDSS will provide clinically meaningful information to clinicians, for a more personalised management of the whole spectrum of Metabolic Associated Fatty Liver Disease (MAFLD). MAFLD, with an estimated prevalence of about 25%, goes from an undetected sleeping disease, to inflammation (hepatitis), to fibrosis development (cirrhosis) and/or hepatocellular carcinoma (HCC), decompensated cirrhosis and HCC being the final stages of the disease. However, many MAFLD patients do not die from the liver disease itself, but from cardiovascular comorbidities or complications. The ARTEMIs will contribute to the earlier management of MAFLD patients, by prognosing the development of more advanced forms of the disease and cardiovascular comorbidities, promoting active surveillance of patients at risk. The system will predict the impact of novel drug treatments or procedures, or simply better life habits. The system will therefore not only serve as a clinical decision aid tool, but also as an educational tool for patients, to promote better nutritional and lifestyle behaviors. In more advanced forms of the disease, therapeutic interventions include TIPPS to manage portal hypertension, partial hepatectomy, partial or complete liver transplant. ARTEMIs will contribute to predict per- or post-intervention heart failure, building on existing microcirculation hemodynamics models. The model developers will benefit from a large distributed patient cohort and data exploration environment to identify patterns in data, draw new theories on the liver-heart metabolic axis and validate the performance of their models. The project includes a proof-of-concept feasibility study assessing the utility of the integrated virtual twins and CDSS in the clinical context.


Bournemouth University ?
Albert-Ludwigs-Universitaet Freiburg 501 000 €
Assistance Publique Hopitaux de Paris 424 937 €
BC Platforms 936 500 €
Betthera s.r.o. 185 000 €
Charite - Universitaetsmedizin Berlin 296 500 €
Cliniques Universitaires Saint-LUC ASBL 296 500 €
Deutsches Krebsforschungszentrum Heidelberg 920 586 €
European Liver Patients Association 199 000 €
Fondation Cardiometabolisme Nutrition 475 000 €
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca 724 000 €
Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana 300 875 €
Institut National de Recherche en Informatique et Automatique 1 216 250 €
Matical Innovation SL 477 125 €
Medical Research Infrastructure Development AND Health Services Fund BY THE Sheba Medical Center 66 000 €
Medizinische Universitaet Wien 353 750 €
Universita Degli Studi Di Roma LA Sapienza 151 722 €
Universitaet Leipzig 766 595 €
Universitatsklinikum Heidelberg 395 250 €
Universitatsklinikum Jena 678 505 €

https://cordis.europa.eu/project/id/101136299

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Bournemouth University EDUCATIONAL CORPORATION, Poole, Royaume Uni.